Sector
PharmaceuticalsOpen
₹4,889.95Prev. Close
₹4,881.7Turnover(Lac.)
₹1,588.57Day's High
₹4,950Day's Low
₹4,804.5552 Week's High
₹6,439.952 Week's Low
₹4,407.05Book Value
₹1,050.35Face Value
₹2Mkt Cap (₹ Cr.)
57,816.25P/E
26.09EPS
187.04Divi. Yield
0.82This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 23.91 | 23.91 | 23.91 | 23.91 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,530.7 | 9,325.94 | 8,719.75 | 7,601.84 |
Net Worth | 10,554.61 | 9,349.85 | 8,743.66 | 7,625.75 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 8,829.81 | 7,219.68 | 6,677.08 | 5,300.26 |
yoy growth (%) | 22.3 | 8.12 | 25.97 | 16.53 |
Raw materials | -3,565.89 | -2,665.02 | -2,550.56 | -2,075.22 |
As % of sales | 40.38 | 36.91 | 38.19 | 39.15 |
Employee costs | -1,434.49 | -1,158.72 | -1,066.76 | -861.63 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 1,753.37 | 1,897.08 | 1,338.08 | 934.29 |
Depreciation | -218.98 | -198.93 | -186.84 | -107.65 |
Tax paid | -212.12 | -199.22 | -73.66 | -218.45 |
Working capital | 954.38 | 1,212.29 | 1,245.84 | 514.21 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 22.3 | 8.12 | 25.97 | 16.53 |
Op profit growth | -7.11 | 32.79 | 47.85 | 13.05 |
EBIT growth | -7.66 | 40.9 | 42.42 | 5.28 |
Net profit growth | -8.53 | 33.26 | 76.63 | -18.94 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 12,667.58 | 11,599.26 | 10,634.19 | 8,865.01 | 8,344.36 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 310.84 | 216.08 | 162.65 | 233.21 | 104.22 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,698.35 | 129.24 | 4,07,155.15 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,549.7 | 71.05 | 1,47,295.24 | 594 | 0.54 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,444.25 | 25.07 | 1,16,664.33 | 1,438.15 | 0.9 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183.9 | 59.03 | 1,07,673.27 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,458.1 | 52.42 | 1,01,358.17 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
Basudeo N Singh
Managing Director
SANDEEP SINGH
Executive Director
Mritunjay Kumar Singh
Non-Exec. & Independent Dir.
A K Purwar
Non-Exec. & Independent Dir.
SANGEETA KAPILJIT SINGH
Non-Exec. & Independent Dir.
SUDHA RAVI
Company Sec. & Compli. Officer
Manish Narang
Non-Exec. & Independent Dir.
Narendra Aneja
Executive Director
SARVESH SINGH
Executive Director
Madhurima Singh
Independent Director
Sujjain Talwar
Executive Director
Srinivas Singh
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Alkem Laboratories Ltd
Summary
Headquartered in Mumbai, India, Alkem Laboratories Limited is a leading Indian pharmaceutical company with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales. The company also has presence in more than 40 international markets, with the United States being its key focus market. Alkem Laboratories Ltd was incorporated as a private limited company on August 8, 1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of Company was changed to Alkem Laboratories Limited with effect from October 26, 1988.In 1978, the company established its first plant at Taloja Maharashtra. In 1992, the company established its manufacturing facility in Mandwa, Maharashtra, which was later converted into an API facility in 2005. In 2003, the company set up a research and development facility for ANDA development
Read More
The Alkem Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹4835.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alkem Laboratories Ltd is ₹57816.25 Cr. as of 01 Apr ‘25
The PE and PB ratios of Alkem Laboratories Ltd is 26.09 and 4.96 as of 01 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Alkem Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alkem Laboratories Ltd is ₹4407.05 and ₹6439.9 as of 01 Apr ‘25
Alkem Laboratories Ltd's CAGR for 5 Years at 16.33%, 3 Years at 11.45%, 1 Year at -3.46%, 6 Month at -21.39%, 3 Month at -13.20% and 1 Month at 5.11%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.